ArticlePharmaceutical research2011
Identification of a LNCaP-specific binding peptide using phage display.
Article in Pharmaceutical research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Genetically engineered bacteriophages as novel nanomaterials: applications beyond antimicrobial agents.Frontiers in bioengineering and biotechnology · 2024Review
- Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.Journal for immunotherapy of cancer · 2019Article
- Efficient Prostate Cancer Therapy with Tissue-Specific Homing Peptides Identified by Advanced Phage Display Technology.Molecular therapy oncolytics · 2019Article
- Functional peptides for siRNA delivery.Advanced drug delivery reviews · 2017Review
- Intracellular trafficking and exocytosis of a multi-component siRNA nanocomplex.Nanomedicine : nanotechnology, biology, and medicine · 2016Article
- Discovery of Peptide ligands for hepatic stellate cells using phage display.Molecular pharmaceutics · 2015Article
- Phage display and targeting peptides: surface functionalization of nanocarriers for delivery of small non-coding RNAs.Frontiers in genetics · 2015Article
- Peptides used in the delivery of small noncoding RNA.Molecular pharmaceutics · 2014Review
- Prostate cancer relevant antigens and enzymes for targeted drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Development of streptavidin-based nanocomplex for siRNA delivery.Molecular pharmaceutics · 2013Article
- Development of cholesteryl peptide micelles for siRNA delivery.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Identification of chondrocyte-binding peptides by phage display.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2013Article
- Expression profile and functional activity of peptide transporters in prostate cancer cells.Molecular pharmaceutics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo identify a LNCaP-specific peptide using a phage display library and evaluate its potential applications in targeted drug delivery.
methodsBinding abilities of selected phages were evaluated by cell phage ELISA. The KYL peptide encoded by the most specific phage clone was synthesized, labeled with fluorescein, and assayed in various cell lines. A fusion peptide composed of the KYL peptide and a proapoptotic peptide ( D )(KLAKLAK)(2) was synthesized, and the cell death effect was evaluated on different cells. Moreover, the KYL peptide was conjugated to a cationic protein, protamine, to explore its potential application in siRNA delivery.
resultsOne phage clone with a high binding affinity to LNCaP cells was identified. Cell phage ELISA and immunostaining demonstrated high specificity of this phage to LNCaP cells. The fluorescein-labeled KYL peptide exhibited higher binding to LNCaP cells in comparison to other cells. The fusion peptide composed of the KYL peptide and the proapoptotic peptide induced cell death in LNCaP cells, but not in PC-3 cells. The KYL peptide-protamine conjugate also efficiently delivered a fluorescein-labeled siRNA into LNCaP cells.
conclusionWe identified a LNCaP-specific peptide and demonstrated its potential applications in targeted drug delivery to LNCaP cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.